Global preimplantation genetic diagnosis market is estimated to witness high growth, owing to rising adoption of automation and growing need to minimize medication errors
Global Preimplantation Genetic Diagnosis Market is estimated to be valued at USD 57.1 Mn in 2024, exhibiting a CAGR of 7.6% over the forecast period 2024-2031. Increased focus on prevention of genetic disorders through preimplantation genetic diagnosis (PGD) can drive the market growth.
Market Dynamics:
Increasing awareness about genetic disorders and hereditary conditions amongst consumers encourages people to opt for PGD to screen embryos for genetic abnormalities before implantation. This helps in prevention of transmission of genetic diseases to offspring. Continuous technological advancements in assisted reproductive technologies such as IVF improves the success rate of PGD procedures. Modern techniques enable extraction of single cell from embryo and amplification of DNA for comprehensive screening without hampering the viability of embryo.
Increasing Incidence of Genetic Disorders
Global preimplantation genetic diagnosis market growth is driven by rising incidence of genetic disorders across the world. Genetic disorders are caused when there are changes or mutations in genes or chromosomes. Some common genetic disorders include cystic fibrosis, muscular dystrophy, hemophilia, sickle cell anemia, and others. According to the World Health Organization (WHO), around 6-8% of babies are born with a serious genetic or congenital disorder worldwide every year. As genetic testing helps identify genetic abnormalities in embryos and allows selection of healthy embryos for implantation, it witness huge demand from infertile couples and individuals with a family history of genetic disorders.
Advances in IVF and Embryo Biopsy Techniques
Ongoing advancement in in-vitro fertilization (IVF) and embryo biopsy techniques can drive the market growth. IVF enables fertilization to occur outside the body in a laboratory by combining an egg and sperm in a culture dish. Embryo biopsy involves removing few cells from an embryo without damaging it for genetic testing. Improvements in IVF protocols and techniques such as intracytoplasmic sperm injection (ICSI) have increased fertilization and pregnancy success rates. Progress in less invasive embryo biopsy methods such as polar body biopsy and blastomere biopsy allow testing at early stages without compromising embryo viability. The development of new techniques increases the uptake of PGD among couples and help to identify healthy embryos more efficiently and safely.
Limited Awareness
Limited public awareness about PGD and its advantages can hamper the market growth. Many people, especially in developing nations, still have low understanding about genetic disorders, inheritance patterns, and the role of PGD in selecting unaffected embryos. This leads to lower adoption of these technologies as compared to developed countries where awareness levels are higher. Extensive educational and promotional initiatives are needed to increase awareness among target populations and healthcare professionals.
Ethical Considerations and Regulatory Barriers
Ethical issues surrounding the use of PGD can hamper the market growth. There are concerns that it may encourage discrimination based on genetic makeup and disability. Some religious people also view it as interfering with natural conception processes. Moreover, the regulations governing PGD vary widely across countries. While it is legal in many developed nations, certain applications remain banned or restricted in some parts of the world due to socio-religious beliefs. Complying with complex and stringent regulations increases the costs involved.
Rising Public-Private Investments
Increasing investments by government and private organizations in PGD research can offer opportunities for industry players. Many developing countries are investing heavily to build new fertility centers, train medical professionals, and spread awareness about assisted reproductive technologies including PGD. Companies are investing more in the development of advanced preimplantation genetic screening (PGS) platforms using latest techniques like next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH). This will potentially facilitate testing of all 24 chromosomes of embryos, enabling comprehensive chromosomal aneuploidy screening. Such collaborative initiatives are helping overcome infrastructure and cost challenges, thus, driving the market growth.
Innovations in Non-Invasive PGD Methods
The introduction of novel non-invasive methods for PGD using emerging technologies can offer attractive opportunities. Researchers are working on techniques like embryo culture media analysis and time-lapse microscopy that can assess embryo health without biopsy. Some innovations analyze cell-free DNA or microRNAs in spent embryo culture media for genetic evaluation. If proven effective, such non-invasive approaches will address current limitations like risks of biopsy, costs, and extend PGD access. Continuous R&D develops patient-friendly and affordable solutions, thus, driving the market growth.
Link - https://www.coherentmarketinsights.com/market-insight/preimplantation-genetic-diagnosis-market-698
Key Development
- In May 2024, Takara Bio USA, Inc., a subsidiary of Takara Bio Inc., launched the Lenti-X Transduction Sponge, a novel microfluidic transduction enhancer for lentivirus-mediated gene delivery. This innovative product simplifies the process with a walkaway workflow, achieving high transduction efficiency across cell types. President & CEO Carol Lou highlighted its potential to revolutionize viral transduction methods, offering a reliable and non-toxic alternative to chemical enhancers, thereby streamlining research and reducing costs.
- In April 2024, GenEmbryomics Limited, a trailblazer in advanced genetic testing services for embryos, and Progenesis Inc, a top provider of preimplantation genetic testing for in vitro fertilization (IVF), announced a transformative partnership aimed at expanding access to state-of-the-art reproductive technologies
- In June 2023, Kindbody, a prominent fertility clinic network and provider of family-building benefits for employers, launched Kindlabs, its new genetic testing division. This addition integrates genomics into Kindbody's comprehensive care model, enhancing patient services. Kindlabs operates a state-of-the-art reference laboratory spanning 8,000 square feet in Secaucus, NJ.
Key Players: PerkinElmer, Inc., Genea Limited, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Quest Diagnostics Incorporated, Illumina, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), LabCorp of America Holdings (Laboratory Corporation of America), Natera, Inc., Oxford Gene Technology, California Pacific Medical Center, Good Start Genetics, Inc., Invitae Corporation, F. Hoffmann-La Roche AG, Progenesis
